Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study

被引：0

作者：

Torres, Tiago ^{[1
,2
]}

Yeung, Jensen ^{[3
,4
,5
,6
]}

Prajapati, Vimal H. ^{[7
,8
,9
,10
]}

Ribero, Simone ^{[11
]}

Balato, Anna ^{[12
]}

Marzano, Angelo Valerio ^{[13
,14
]}

Cruz, Maria Joao ^{[15
,16
]}

Paiva Lopes, Maria Joao ^{[17
,18
,19
]}

Lazaridou, Elizabeth ^{[20
]}

Carrascosa, Jose-Manuel ^{[21
]}

Alvarenga, Jose Miguel ^{[1
]}

Farinha, Pedro ^{[17
,18
,19
]}

Duarte, Bruno ^{[17
,18
,19
]}

Munera-Campos, Monica ^{[21
]}

Sood, Siddhartha ^{[22
]}

Rankin, Brian D. ^{[7
]}

Ortoncelli, Michela ^{[11
]}

Caccavale, Stefano ^{[12
]}

Ferrucci, Silvia Mariel ^{[13
]}

Pires Rosa, Gilberto ^{[15
,16
]}

Daponte, Athina Ioanna ^{[20
]}

Silvi, Gianmarco ^{[23
]}

Peris, Ketty ^{[24
,25
]}

Gori, Niccolo ^{[24
,25
]}

Prignano, Francesca ^{[23
]}

Kolios, Antonio ^{[26
,27
]}

Herranz, Pedro ^{[28
]}

Gregoriou, Stamatios ^{[29
]}

Rompoti, Natalia ^{[29
]}

Gkalpakiotis, Spyridon ^{[30
,31
]}

Chiricozzi, Andrea ^{[24
,25
]}

机构：

[1] Ctr Hosp Univ Santo Antonio Porto, Dept Dermatol, Rua Dom Manuel II 57, P-4050342 Porto, Portugal

[2] Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal

[3] Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada

[4] Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada

[5] Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada

[6] Prob Med Res, Toronto, ON, Canada

[7] Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada

[8] Dermatol Res Inst, Calgary, AB, Canada

[9] Skin Hlth & Wellness Ctr, Calgary, AB, Canada

[10] Prob Med Res, Calgary, AB, Canada

[11] Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy

[12] Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

[13] Fdn IRCCS Cagranda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[14] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[15] Unidade Local Saude Sao Joao, Dept Dermatol, Porto, Portugal

[16] Univ Porto, Fac Med, Porto, Portugal

[17] Hosp S Jose, Dermatol Dept, Unidade Local Saude Sao Jose, Lisbon, Portugal

[18] Ctr Clin Acad Lisboa, Lisbon, Portugal

[19] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, NMS,FCM, Lisbon, Portugal

[20] Aristotle Univ Thessaloniki, Dept Dermatol Venereol 2, Sch Med, Thessaloniki, Greece

[21] Hosp Univ Germans Trias I Pujol, Serv Dermatol, Badalona, Barcelona, Spain

[22] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada

[23] Univ Florence, Dept Hlth Sci Dermatol, Florence, Italy

[24] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, Dermatol, Rome, Italy

[25] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, UOC Dermatol, Rome, Italy

[26] Univ Zurich, Dept Dermatol, Zurich, Switzerland

[27] Inselspital Univ Hosp Bern, Bern, Switzerland

[28] Hosp La Paz, Dept Dermatol, Madrid, Spain

[29] Natl & Kapodistrian Univ Athens, A Sygros Hosp Skin & Venereal Dis, Fac Med, Dept Dermatol Venereol, Athens, Greece

[30] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Dermatovenereol, Prague, Czech Republic

[31] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

来源：

DERMATOLOGY AND THERAPY | 2025年 / 15卷 / 08期

关键词：

Atopic dermatitis; Dupilumab; Effectiveness; Safety; Tralokinumab; Upadacitinib;

D O I：

10.1007/s13555-025-01453-8

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

IntroductionEvaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged >= 12 years.MethodsEffectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs).ResultsA total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-na & iuml;ve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics.ConclusionThis study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib's superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.

引用

页码：2295 / 2305

页数：11

共 9 条

[1] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial [J].

Blauvelt, Andrew ;

Teixeira, Henrique D. ;

Simpson, Eric L. ;

Costanzo, Antonio ;

De Bruin-Weller, Marjolein ;

Barbarot, Sebastien ;

Prajapati, Vimal H. ;

Lio, Peter ;

Hu, Xiaofei ;

Wu, Tianshuang ;

Liu, John ;

Ladizinski, Barry ;

Chu, Alvina D. ;

Eyerich, Kilian .

JAMA DERMATOLOGY, 2021, 157 (09) :1047-1055

[2] Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study [J].

Calabrese, Laura ;

Cinotti, Elisa ;

D'onghia, Martina ;

Cartocci, Alessandra ;

Rubegni, Pietro ;

Maccari, Francois ;

Boulard, Claire ;

Reguiai, Ziad ;

Becherel, Pierre Andre ;

Jacobzone, Caroline ;

Begon, Edouard ;

Fite, Charlotte ;

Walls, Beatrice ;

Liegeon, Anne Laure ;

Parier, Josiane ;

Chaby, Guillaume ;

Perrot, Jean-Luc .

ACTA DERMATO-VENEREOLOGICA, 2025, 105

[3] Systemic Immunomodulatory Treatments for Atopic Dermatitis Living Systematic Review and Network Meta-Analysis Update [J].

Drucker, Aaron M. ;

Lam, Megan ;

Prieto-Merino, David ;

Malek, Rayka ;

Ellis, Alexandra G. ;

Yiu, Zenas Z. N. ;

Rochwerg, Bram ;

Di Giorgio, Sonya ;

Arents, Bernd W. M. ;

Mohan, Tanya ;

Burton, Tim ;

Spuls, Phyllis I. ;

Schmitt, Jochen ;

Flohr, Carsten .

JAMA DERMATOLOGY, 2024, 160 (09) :936-944

[4] Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis [J].

Drucker, Aaron M. ;

Lam, Megan ;

Elsawi, Rawaan ;

Prieto-Merino, David ;

Malek, Rayka ;

Ellis, Alexandra G. ;

Yiu, Zenas Z. N. ;

Rochwerg, Bram ;

Di Giorgio, Sonya ;

Arents, Bernd W. M. ;

Burton, Tim ;

Spuls, Phyllis, I ;

Schmitt, Jochen ;

Flohr, Carsten .

BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) :184-190

[5] Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients [J].

Ferrucci, Silvia ;

Tavecchio, Simona ;

Maronese, Carlo Alberto ;

Balato, Anna ;

Di Brizzi, Eugenia Veronica ;

Ortoncelli, Michela ;

Ribero, Simone ;

Girolomoni, Giampiero ;

Maurelli, Martina ;

Fortina, Anna Belloni ;

Caroppo, Francesca ;

Naldi, Luigi ;

Pezzolo, Elena ;

Nettis, Eustachio ;

Pugliese, Francesco ;

Stingeni, Luca ;

Hansel, Katharina ;

Rubegni, Giovanni ;

Calabrese, Laura ;

Russo, Filomena ;

Gola, Massimo ;

Magnaterra, Elisabetta ;

Rongioletti, Franco ;

Mercuri, Santo Raffaele ;

Paolino, Giovanni ;

Savoia, Paola ;

Veronese, Federica ;

Foti, Caterina ;

Ambrogio, Francesca ;

Scalvenzi, Massimiliano ;

Napolitano, Maddalena ;

Patruno, Cataldo ;

Dastoli, Stefano ;

Corazza, Monica ;

Borghi, Alessandro ;

Calzavara-Pinton, Pier Giacomo ;

Rossi, Mariateresa ;

Offidani, Annamaria ;

Radi, Giulia ;

Bonzano, Laura ;

Ferreli, Caterina ;

Piras, Viviana ;

Satta, Rosanna ;

Sucato, Federica ;

Malagoli, Piergiorgio ;

Gaiani, Francesca ;

Micali, Giuseppe ;

Musumeci, Maria Letizia ;

Fargnoli, Maria Concetta ;

Esposito, Maria .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (12) :1561-1572

[6] A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients [J].

Hagino, Teppei ;

Saeki, Hidehisa ;

Fujimoto, Eita ;

Kanda, Naoko .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (05) :1049-1055

[7] Patients' preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most [J].

Schaarschmidt, Marthe-Lisa ;

Kromer, Daniel ;

Wellmann, Phoebe ;

Peitsch, Wiebke K. ;

Kromer, Christian .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)

[8] Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis [J].

Silverberg, Jonathan I. ;

Gooderham, Melinda ;

Katoh, Norito ;

Aoki, Valeria ;

Pink, Andrew E. ;

Binamer, Yousef ;

Rademaker, Marius ;

Fomina, Daria ;

Gutermuth, Jan ;

Ahn, Jiyoung ;

Valenzuela, Fernando ;

Ameen, Mahreen ;

Steinhoff, Martin ;

Kirchhof, Mark G. ;

Lio, Peter ;

Wollenberg, Andreas .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (11) :2139-2148

[9] Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis [J].

Torres, Tiago ;

Petersen, Anne Sohrt ;

Ivens, Ulla ;

Vilaro, Albert Bosch ;

Stinson, John ;

Carrascosa, Jose Manuel .

DERMATOLOGY AND THERAPY, 2024, 14 (04) :983-992

← 1 →